NunaBio is a privately owned specialist DNA development company focused on synthetic DNA production for cutting-edge biotechnology solutions. Operating in the rapidly growing global market for DNA, NunaBio serves a diverse range of clients, including those in custom synthesis, contract research, and material supply. The company leverages its core expertise in research and development into cell-free DNA synthesis, process optimization, route design, scale-up, and small-scale manufacture for clinical studies. NunaBio's business model revolves around providing tailored solutions to meet specific client needs, ensuring high-quality and reliable DNA synthesis through enzymatic processes. The company generates revenue through custom synthesis contracts, research partnerships, and material supply agreements. NunaBio's commitment to innovation is evidenced by its recent pre-seed funding round and the appointment of key leadership positions. The company operates with a culture of inclusion, growth, and originality, supported by resources that enable individuals to thrive and make a significant impact.

Keywords: synthetic DNA, biotechnology, cell-free synthesis, process optimization, clinical studies, custom synthesis, contract research, material supply, enzymatic processes, innovation.